-
Vaccines and Neurodegeneration: Lessons for Huntington’s Disease?
Latest News
-
UniQure Secures Type A Meeting with FDA: What This Means for AMT-130
⏱️6 min read | UniQure secured a Type A FDA meeting, a high-priority discussion for urgent issues. Within 30 days, both sides will discuss what kind of data package might support the advancement of AMT-130 in the US.
-
Interview: CHDI Management
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
-
CHDI Report: Day 3
Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies
-
CHDI Report: Day 2
Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD
-
CHDI Report: Day 1
Day 1 of CHDI’s HD therapeutics conference: exploring abnormal brain connections and silencing the HD gene
-
Anti-nausea drug helps cells with the HD mutation stay healthy in a surprising way
Anti-nausea drug meclizine protects cells with the HD mutation from death by reducing cellular energy production
-
HDBuzz takes your questions to the annual therapeutics meeting of CHDI
HDBuzz visits Palm Springs to talk with CHDI about the latest HD research. Send us your questions!
-
Welcome to HDBuzz
Welcome to HDBuzz. Huntington’s disease research news. In plain language. Written by scientists. For the global HD co
-
Memantine in HD: dose is everything
Memantine, a drug already used in Alzheimer’s disease, might help in HD, but a mouse study shows dose is everything.
-
An active lifestyle may make a difference to HD symptoms
More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.
-
Frequently asked questions, January 2011
Answers to frequently-asked questions about HD – the first in a regular series of HDBuzz FAQ articles.
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
